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Background: Ranolazine decreases the frequency of arrhythmias
during the acute phases of ischemic heart disease (IHD), but it
remains unknown if it has similar effects in the chronic phase of the
disease. We performed a prospective, randomized, cross-over pilot
trial to test the hypothesis that chronic treatment with ranolazine
can reduce the incidence of documented arrhythmias and the related
symptoms of palpitation in stable patients with IHD.
Methods: We randomized 105 patients with stable IHD and
symptoms of angina and palpitations already on therapy with beta-
blockers and/or calcium antagonists to ranolazine (750 mg bid,
N = 53) or placebo (N = 52) for 30 days (until T-1). After a wash-
out period to avoid any carryover effect, cross-over was
performed,and patients were switched to the other drug which was
continued for 30 days (until T-2). All patients underwent symptom-
limited exercise stress testing and 48-hour ECG Holter monitoring at
T1 and T2. During the study period, patients were told to use a
OmronN® portable ECG monitor HCG-801 device in case of
symptoms of palpitations.
Results: Ranolazine reduced the number of anginal episodes more
commonly than placebo (5 ± 8 episodes/30 days vs. 21 ± 24 epi-
sodes/30 day, p = 0.001) and increased exercise durations at 1 mm
ST-segment depression (514 ± 211 s vs. 402 ± 287 s, p = 0.025)
and at onset of angina (614 ± 199 s vs. 519 ± 151 s, p = 0.007) at
stress testing.
These effects were coupled by signiﬁcant decreases with
ranolazine as compared with placebo treatment periods in the
occurrence of frequent (N1000 beats) supraventricular arrhythmias
(33% vs 52%, p = 0.01) and complex ventricular arrhythmias (17% vs
30%, p = 0.045). Complete resolution of symptoms of palpitations
was signiﬁcantly more common with ranolazine than placebo (31/53
vs 16/52 patients, p = 0.008). Also, portable ECG recordings showed
that arrhythmias were less common during ranolazine vs. placebo,
with signiﬁcant decreases in number (7 ± 10 episodes/30 days vs.
23 ± 29 episodes/30 day, p = 0.001) and duration (10 ± 18 min/
30 days vs. 19 ± 21 min/30 day, p = 0.021) of symptomatic arrhyth-
mic episodes. No severe side effects were recorded during the trial
period.
Conclusion: The antianginal and antiischemic properties of ranolazine
are paralleled by signiﬁcant decreases in the occurrence of both
arrhythmias and the related symptoms of palpitations in stable patients
with IHD. (ClinicalTrials.gov identiﬁer: NCT01495520).
doi:10.1016/j.ijcme.2015.05.016
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Background: Prompt reperfusion with percutaneous coronary
intervention (PCI) in ST-elevation myocardial infarction (STEMI)
improves clinical outcomes through salvage of myocardial tissue.
Although use of thrombus aspiration with PCI can improve epicardial
ﬂow and myocardial perfusion, several unmet needs remain. The
purpose of this trial was to evaluate the hypothesis that local
delivery of low-dose thrombolytics can enhance the efﬁcacy of
thrombus aspiration in STEMI patients undergoing primary PCI.
Methods: A total of 102 patients with STEMI and angiographic
evidence of totally occlusive thrombosis in the culprit artery were
randomly assigned to receive local bolus of 200,000 units urokinase
(N = 51) or saline solution (N = 51) followed by manual aspiration
thrombectomy (Pronto™, Vascular Solutions, Inc., Minneapolis,
Minnesota) and PCI. Both groups received abciximab (i.v. bo-
lus + 12-h infusion). End points included ﬁnal thrombolysis in
myocardial infarction (TIMI) ﬂow grade, frame count, and thrombus
grade N 2, myocardial blush grade (MBG), 60-min ST-segment
resolution (STR) N 70%, and 6-month clinical outcomes. All patients
had echocardiography at 6-month and left ventricular ejection
fraction (EF) and wall motion score (WMS) were obtained.
Results: Baseline clinical and angiographic characteristics of both
groups were similar. Local urokinase was associated with post-PCI
evidence of higher TIMI ﬂow grade 3 (96% vs. 68%; p = 0.027), lower
TIMI frame count (18 ± 11 vs. 25 ± 13; p = 0.045) and fewer TIMI
thrombus grade N 2 (20% vs. 52%; p = 0.039). Histopathologic
evaluation performed in 11 Gr. A and 11 Gr. B patients showed that
aspirated thrombi after urokinase were smaller, softer and less
organized than after saline. Post-PCI myocardial perfusion was
slightly increased with urokinase (MBG 2/3: 88% vs. 64%;
p = 0.09), with signiﬁcantly more patients showing STR N 70% (80%
vs 56%, p = 0.001). No differences between the two groups were
subsequently seen in clinical outcomes and EF, whereas 6-month
WMS was signiﬁcantly lower in patients receiving local urokinase
than saline (1.21 ± 0.29 vs 1.45 ± 0.32, p = 0.008).
Conclusion: Local delivery of low-dose thrombolytics before
thrombectomy in STEMI patients undergoing primary PCI is associ-
ated with improved coronary ﬂow, myocardial perfusion, and 6-
month regional myocardial function. Delivery of low-dose thrombo-
lytic agents directly to the site of thrombus might be an effective
strategy to enhance efﬁcacy of thrombus aspiration in primary PCI.
(ClinicalTrials.gov identiﬁer: NCT01568931).
doi:10.1016/j.ijcme.2015.05.017
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coronary artery disease patients with normal platelet reactivity
while on dual antiplatelet therapy — The PEARL randomized
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Background: Levels of platelet reactivity in patients on dual
antiplatelet therapy (DAPT) can potentially be inﬂuenced by
concomitant treatment with statins that inhibit the CYP3A4 system
involved in the activation of clopidogrel. Recent studies have shown
that a high platelet reactivity during co-administration of clopidogrel
and a CYP3A4-metabolized statin (i.e. atorvastatin) can be lowered
by switching to a non-CYP3A4-metabolized statin (i.e. rosuvastatin).
Aim of this study was to verify if atorvastatin and rosuvastatin have
different pharmacodynamic effects also when they are given to
patients with coronary artery disease (CAD) with baseline normal
platelet reactivity while on DAPT.
Methods: A total of 100 stable CAD patients receiving DPAT
(clopidogrel 75 mg plus aspirin 100 mg) who had evidence of normal
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